Travere Therapeutics Bets Big on FILSPARI Momentum

Travere Therapeutics, Inc. ((TVTX)) has held its Q1 earnings call. Read on for the main highlights of the call.

Travere Therapeutics’ latest earnings call painted a picture of a company with strong momentum but meaningful near‑term costs. Management highlighted a landmark FDA win in FSGS, rapid FILSPARI sales growth, and improving non‑GAAP profitability, while acknowledging higher expenses, GAAP losses, and some early‑launch frictions in reimbursement and physician education.

First FDA Approval in FSGS — Commercial Breakthrough

FILSPARI secured full FDA approval for focal segmental glomerulosclerosis in April, marking the first and only approved therapy for this rare and serious kidney disease. Travere estimates more than 30,000 eligible FSGS patients in the U.S. and over 100,000 across IgA nephropathy and FSGS combined, supporting a modeled peak sales opportunity of about $3 billion.

FILSPARI Demand Surges Despite Seasonal Headwinds

Commercial momentum for FILSPARI remained strong, with 993 new patient start forms in the quarter and U.S. net product sales of $105.2 million. That represents roughly 88% year‑over‑year growth, achieved despite typical first‑quarter insurance resets, gross‑to‑net pressures, and fewer shipping weeks that delayed recognition of some demand into Q2.

Revenue Base Broadens Beyond Flagship Drug

Total U.S. net product sales reached $124.5 million and total revenue came in at $127.2 million for the quarter, underscoring a diversified top line. While FILSPARI drove the bulk of sales, Thiola and Thiola EC contributed $19.3 million and licensing and collaboration revenue added $2.7 million.

Non‑GAAP Profitability Marks a Turning Point

On a non‑GAAP basis Travere delivered adjusted net income of $4.1 million, or $0.05 per share, a sharp improvement from a $16.9 million loss and negative $0.19 per share a year earlier. The shift underscores improving underlying profitability even as the company leans into heavier commercial and R&D spending.

HARMONY Phase III Restart Re‑energizes Pipeline

The company restarted enrollment in its pivotal Phase III HARMONY study of pegtibatinase for classical homocystinuria and dosed the first new patient. Travere is targeting a global addressable population of roughly 7,000 to 10,000 patients, with top‑line HARMONY data expected in 2027, setting up a potential second rare‑disease growth pillar.

New Data Strengthen FILSPARI’s Clinical Profile

Additional clinical and real‑world evidence continued to validate FILSPARI’s efficacy and safety. PROTECT data showed patients achieving proteinuria below 0.3 g/g experienced annual eGFR decline under 1 mL per minute, while DUPLEX and CJASN findings demonstrated sustained proteinuria reductions and consistent outcomes in genetic FSGS, supporting deeper physician adoption.

Liquidity Position Supports Investment Cycle

As of March 31 the company held roughly $352 million in cash, cash equivalents, marketable securities and receivables, including about $264.7 million of cash and a $25 million milestone received after quarter‑end. Management indicated this balance sheet provides adequate runway to fund the FSGS launch and advance key pipeline programs.

Operating Costs Climb with Growth Initiatives

R&D expenses increased to $57.1 million on a GAAP basis, or $51.5 million non‑GAAP, driven largely by the HARMONY restart and broader development work. SG&A spending rose to $80.3 million GAAP, or $69.3 million non‑GAAP, as Travere invests in the FILSPARI launch and commercial infrastructure to capture its expanding renal opportunity.

Royalty and Accounting Shifts Pressure Margins

Royalty expense roughly doubled to $24.8 million from $12.4 million, reflecting changes in amortization presentation and the end of Thiola’s intangible life. These shifts introduce more volatility into near‑term expenses and weigh on reported operating margins, even as underlying product demand trends remain favorable.

GAAP Loss Highlights Ongoing Investment Phase

Despite non‑GAAP profitability Travere still posted a GAAP net loss of $37.1 million, or $0.40 per share, modestly better than the $41.2 million loss a year earlier. The gap between GAAP and non‑GAAP results underscores the current cash‑burn profile and the cost of scaling a rare‑disease franchise and pipeline simultaneously.

Timing and Recognition Mask Underlying Strength

Management noted that the quarter included fewer shipping weeks and typical early‑year gross‑to‑net headwinds tied to insurance resets. Some FILSPARI shipments will therefore show up in Q2 figures, meaning reported Q1 revenue understated the underlying demand trend that the company says remains robust.

Education Gaps and Early Launch Uncertainties

The FSGS launch is still in its early innings and management flagged ongoing education needs with physicians and payers, including confusion over “active nephrotic syndrome” versus nephrotic‑range proteinuria. Travere also withheld detailed indication‑level metrics and conversion rates from patient start forms, leaving some near‑term visibility gaps for investors.

Execution and Competitive Risks Around the Pipeline

While pegtibatinase benefits from Breakthrough Therapy designation and prior FDA alignment on its primary endpoint, the 2027 HARMONY timeline carries execution risk over several years. Meanwhile, competition in IgA nephropathy is intensifying as new therapies enter the market, keeping pricing and share dynamics in flux for FILSPARI.

Guidance and Outlook: Growth Now, Profits Later

Management guided to continued strong FILSPARI demand and a larger, faster FSGS launch, pointing to nearly 1,000 new start forms, 88% sales growth, and broad payer access covering most eligible patients. They reiterated plans for elevated commercial and R&D investment, highlighted a solid $352 million liquidity base, and pointed to 2027 HARMONY data as the next major catalyst for long‑term growth.

Travere’s call ultimately balanced bullish commercial momentum and a derisked renal franchise against the realities of higher costs and lingering GAAP losses. For investors, the story hinges on sustained FILSPARI uptake toward a multibillion‑dollar peak, successful execution in HARMONY, and the company’s ability to translate today’s rare‑disease leadership into durable earnings power over the next several years.